本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 09 日(星期二) 16:00-17:00 证券代码：688606 证券简称：奥泰生物 公告编号：2025-039 杭州奥泰生物技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow. sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 09 月 02 日(星期二)至 09 月 08 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 yanping.fu@ alltests.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 杭州奥泰生物技术股份有限公司（以下简称"公司"）已于 2025 年 08 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 ...

杭州奥泰生物技术股份有限公司 2025 年度"提质增效重回报"行动方案的 2、加大研发投入，持续研发成果产业化 公司高度重视技术研发和自主创新，经过多年的技术积累，构建了生物原料 技术平台、POCT 快速诊断技术平台、生化技术平台、化学发光技术平台、电子 仪器技术平台、生物传感电化学技术平台、免疫印迹技术平台、分子诊断技术平 台等八大技术平台，并形成了单克隆抗体制备技术，小分子抗原制备技术，纳米 级免疫胶体金标记技术，时间分辨免疫荧光技术，干式化学分析技术，生物传感 电化学技术等多项核心技术，均应用于自产产品并逐步实现产业化。2025 年上 半年，公司研发投入 4,819.57 万元，占公司营业收入的比例为 11.21%，公司上 市新产品达 140 个，公司新增授权专利/软件著作权共 23 项，新增国内外医疗器 械产品认证 203 项。截至 2025 年 6 月 30 日，公司累计获得授权专利/软件著作 权 219 项，其中发明专利 42 项、实用新型专利 88 项、外观设计专利 79 项、软 件著作权 10 项，累计已取得国内外医疗器械备案以及产品注册证书 3,058 项。 3、积极布局国内外市场，齐头迸进 ...

杭州奥泰生物技术股份有限公司 2025年半年度募集资金存放与实际使用情况的专项 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会《关于同意杭州奥泰生物技术股份有限公司首 次公开发行股票注册的批复》(证监许可[2021]495 号)核准同意，公司首次公开 发行人民币普通股 13,500,000 股，发行价格 133.67 元/股，新股发行募集资金 总额为 1,804,545,000.00 元，扣除发行费用 161,278,093.75 元后,募集资金净 额为 1,643,266,906.25 元，上述募集资金已于 2021 年 3 月 19 日全部到位，并 由致同会计师事务所（特殊普通合伙）对公司募集资金的资金到位情况进行了审 验，出具致同验字【2021】第 332C000116 号《验资报告》。公司已按规定对募集 资金进行了专户存储，公司与保荐机构、募集资金专户开户银行签署了《募集资 金三方监管协议》。 （二）募集资金使用情况及结余情况 ...

Group 1 - The core viewpoint of the news is that Aotai Biotech's stock performance and financing activities indicate a high level of market interest, despite a slight decline in stock price on August 26 [1] - On August 26, Aotai Biotech's stock fell by 0.96%, with a trading volume of 36.54 million yuan, and a net financing outflow of 1.52 million yuan [1] - As of August 26, the total margin balance for Aotai Biotech was 78.27 million yuan, accounting for 1.31% of its market capitalization, indicating a high financing balance compared to the past year [1] Group 2 - As of March 31, Aotai Biotech reported a total of 5,431 shareholders, an increase of 3.13% from the previous period, while the average circulating shares per person decreased by 3.04% to 14,597 shares [2] - For the first quarter of 2025, Aotai Biotech achieved a revenue of 208 million yuan, representing a year-on-year growth of 4.28%, and a net profit attributable to shareholders of 61.22 million yuan, up 36.68% year-on-year [2] Group 3 - Aotai Biotech has distributed a total of 1.202 billion yuan in dividends since its A-share listing, with 878 million yuan distributed over the past three years [3] - As of March 31, 2025, Hong Kong Central Clearing Limited was the sixth-largest circulating shareholder of Aotai Biotech, holding 2.4151 million shares, an increase of 757,300 shares from the previous period [3]

Core Viewpoint - The company, Aotai Biological Technology Co., Ltd., is experiencing growth in its financial performance and recognition in the medical device industry, with a notable increase in net profit and various awards for its contributions to ESG and innovation [1][2]. Financial Performance - For Q1 2025, the company reported a revenue of 208 million yuan, representing a year-on-year increase of 4.28% - The net profit for the same period was 61.22 million yuan, showing a significant year-on-year growth of 36.68% - The sales gross margin stood at 55.63% [2]. Market Position - As of August 25, the company's stock closed at 76.17 yuan, with a PE ratio of 18.94 times, and a total market capitalization of 6.039 billion yuan - In comparison, the average PE ratio for the medical device industry is 56.14 times, with a median of 40.36 times, placing Aotai Biological at the 42nd position within the industry [1][2]. Institutional Holdings - By the end of Q1 2025, a total of 15 institutions held shares in Aotai Biological, all of which were funds, with a combined holding of 917,800 shares valued at 6.2 million yuan [1]. Business Overview - Aotai Biological specializes in the research, production, and sales of in vitro rapid diagnostic reagents, focusing on products related to infectious diseases, drug abuse, women's health, COVID-19 testing, tumors, and myocardium [1]. Awards and Recognition - In September 2024, the company was recognized as one of the "Top 20 ESG Strategic Philanthropy Influencers" among listed companies in Hangzhou - In October 2024, it received the "2024 Annual Growth Power Enterprise" award in the inaugural "Future 20" evaluation of Chinese A-share listed companies - In December 2024, it was honored as a "Typical Enterprise in the Construction of Clean Private Enterprises in Zhejiang Province" and ranked among the top 500 innovative enterprises in Zhejiang Province [1].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aotai Biological, which has a current stock price of 75.26 yuan and a rolling PE ratio of 18.71 times, significantly lower than the industry average of 56.58 times [1][2] - Aotai Biological's total market capitalization is 5.967 billion yuan, ranking 41st in the medical device industry based on PE ratio [1][2] - As of the first quarter of 2025, 15 institutions hold shares in Aotai Biological, with a total of 917,800 shares valued at 6.2 million yuan [1] Group 2 - The company reported a revenue of 208 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 4.28%, and a net profit of 61.216 million yuan, which is a 36.68% increase year-on-year [2] - The gross profit margin for Aotai Biological stands at 55.63% [2] - The company specializes in the research, production, and sales of in vitro rapid diagnostic reagents, with key products including those for infectious diseases, drug abuse, women's health, COVID-19 testing, tumors, and myocardium [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aotai Biological, noting its recent stock price increase and low rolling PE ratio compared to the industry average [1][2] - Aotai Biological's stock closed at 77.67 yuan, up 3.20%, with a rolling PE ratio of 19.31, marking a new low in 90 days and a total market capitalization of 6.158 billion yuan [1] - The company ranks 41st in the medical device industry, which has an average PE ratio of 57.51 and a median of 41.25 [1][2] Group 2 - As of the first quarter of 2025, 15 institutions hold shares in Aotai Biological, with a total of 917,800 shares valued at 6.2 million yuan [1] - Aotai Biological specializes in the research, production, and sales of in vitro rapid diagnostic reagents, with key products including infectious disease tests, drug abuse tests, women's health tests, COVID-19 tests, tumor tests, and myocardial tests [1] - The company achieved a revenue of 208 million yuan in the first quarter of 2025, representing a year-on-year growth of 4.28%, and a net profit of 61.216 million yuan, reflecting a year-on-year increase of 36.68% with a gross profit margin of 55.63% [2]

Core Viewpoint - The company has adjusted the grant price of its 2022 restricted stock incentive plan from 25.0725 CNY per share to 23.5992 CNY per share due to the implementation of its 2024 annual profit distribution plan [1][9][11] Summary by Sections Adjustment Details - The adjustment of the grant price is a result of the company's 2024 annual profit distribution, which involved a cash dividend of 1.50 CNY per share, totaling 116.8025 million CNY [9] - The adjusted grant price calculation follows the formula: P = P0 - V, where P0 is the original grant price and V is the cash dividend per share [9] - The new grant price after adjustment is calculated as 25.0725 CNY - 1.4733 CNY = 23.5992 CNY per share [9] Decision-Making Process - The adjustment was approved during the third meeting of the third board of directors and the supervisory board on August 8, 2025 [1][8] - The decision followed the necessary procedures, including independent opinions from the board and supervisory committee [10][11] Impact on the Company - The adjustment of the grant price is not expected to have a substantial impact on the company's financial status or operational results [9] - The stability of the management team and the continuation of the incentive plan are not affected by this adjustment [9] Opinions from Supervisory and Compensation Committees - The supervisory board and the compensation and assessment committee both agree that the adjustment complies with relevant laws and regulations and does not harm the interests of the company or its shareholders [10][11]

Core Viewpoint - The company has announced the cancellation of part of the restricted stock incentive plan from 2022 due to the departure of three incentive recipients, resulting in the cancellation of a total of 6,177 shares that have been granted but not yet vested [8][9]. Summary by Sections 1. Decision Process and Disclosure - The company held a board meeting on June 27, 2022, to approve the draft of the 2022 restricted stock incentive plan and related matters, with independent directors expressing their agreement [1][2]. - The plan was publicly disclosed on June 28, 2022, and the list of initial incentive recipients was announced without any objections from employees [4][5]. 2. Specifics of the Canceled Shares - The cancellation of the restricted stock was due to three recipients leaving the company, which disqualified them from the incentive program, leading to the cancellation of 6,177 shares [8][9]. 3. Impact on the Company - The cancellation of these shares is not expected to have a significant impact on the company's financial status or operational results, nor will it affect the stability of the core team or the ongoing implementation of the incentive plan [8]. 4. Opinions from Supervisory and Compensation Committees - The supervisory board and the compensation and assessment committee both agreed that the cancellation aligns with legal regulations and the incentive plan's provisions, confirming that it does not harm the interests of the company or its shareholders [9][9]. 5. Legal Opinion - The legal firm involved has concluded that the company has fulfilled necessary approvals and disclosures regarding the cancellation, ensuring compliance with relevant regulations [9].

Core Viewpoint - The announcement details the fulfillment of vesting conditions for the third vesting period of the 2022 Restricted Stock Incentive Plan and the second vesting period for reserved grants, allowing a total of 438,890 shares to vest for eligible participants [1][14]. Group 1: Vesting Details - The total number of shares to vest is 438,890, with 409,472 shares from the first grant's third vesting period and 29,418 shares from the reserved grant's second vesting period [1][14]. - The shares are sourced from the company's repurchase of A-share common stock from the secondary market [1]. - The vesting conditions have been met for 94 eligible participants [1][14]. Group 2: Grant and Vesting Arrangements - The initial grant consisted of 770,000 shares (before adjustments), representing approximately 1.4285% of the company's total share capital of 53.904145 million shares [1]. - The vesting schedule includes three periods: 30% after 12 months, 30% after 24 months, and 40% after 36 months from the grant date [3][20]. - The reserved grant includes 50,000 shares, with a vesting condition of 50% after 12 months and another 50% after 24 months [3][20]. Group 3: Performance Assessment - The performance assessment for the incentive plan spans from 2022 to 2024, focusing on both company-level and individual-level performance metrics [5][20]. - Specific performance targets include revenue metrics and the number of approved self-developed products in domestic and international markets [5][20]. - The company-level vesting coefficient is calculated based on the achievement of set revenue and research targets, with a maximum of 100% if all targets are met [5][20].